Hemodynamic Response to Oral Prenalterol in Dilated Decompensated Cardiomyopathy as a Result of Cardiac and Vascular Effects

Guazzi, Maurizio D.; Agostoni, Pier Giuseppe; Doria, Elisabetta; Loaldi, Alesandro; Pepi, Mauro; Polese, Alvise
December 1985
Angiology;Dec1985, Vol. 36 Issue 12, p857
Academic Journal
The initial antifailure efficacy of beta-adrenergic agonists is generally lost during prolonged treatment. The reasons are not fully understood. In 11 patients with advanced cardiac decompensation due to dilated cardiomyopathy, prenalterol, a selective beta, adrenergic agonist, improved the left ventricular contractility after acute intravenous and during prolonged oral administration. However, after periods of treatment ranging from 2 to 18 weeks, blood pressure and systemic vascular resistance were raised in each patient. These changes resulted in an increase of the left ventricular afterload which was such as to overwhelm the effects of the enhanced contractility, and to extinguish the initial improvement of the cardiac function and of the clinical condition. Stimulation of the presynaptical beta-receptors facilitating norepinepbrine release or of the renin secretion by this beta, agonist, may be the causes of the systemic vasoconstriction and of the loss of effectiveness in the long run.


Related Articles

  • Why β-blockers are vital cardiovascular tools. Minhas, Rubin // Pulse;11/1/2004, Vol. 64 Issue 43, p44 

    Focuses on the role of β-blockers in cardiovascular disease medication. Efficacy in cardiovascular disease treatment; Effects of different classes of β-blockers; Adverse effects and contradictions; Considerations for clinical use. INSETS: The shifting ground on β-blockers;2 Summary of...

  • Tolerance due to long-acting beta agonists in asthma.  // American Family Physician;11/1/1995, Vol. 52 Issue 6, p1850 

    Reports on an article published by Grove and Lippworth in the July 22, 1995 issue of `Lancet' on the development of tolerance to long-acting beta-agonists in the treatment of asthma. Two-week washout period during which patients relied on ipratropium for relief of symptoms; Use of salmeterol or...

  • Update on asthma pharmacotherapy. Bell, Edward // Infectious Diseases in Children;Apr2009, Vol. 22 Issue 4, p14 

    The article offers information on the pharmacological management of asthma including beta agonists, inhaled corticosteroids and leukotriene modifiers.

  • Long-term COPD maintenance.  // Clinical Advisor;Jun2014, Vol. 17 Issue 6, p32 

    No abstract available.

  • Budesonide/Formoterol: A Viewpoint by Michael Roth1,2. Michael Roth, Paul W. // Drugs;2004, Vol. 64 Issue 4, p443 

    This article presents views of the author on formoterol. Corticosteroids combined with long-acting J32-agonists, for example budesonide/formoterol, have been suggested for the treatment of inflammatory lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The...

  • Prescribing beta-agonists for respiratory disease. Scullion, Jane; Holmes, Steve // Independent Nurse;4/16/2010, p1 

    The article discusses about beta-agonists which are commonly prescribed to relieve symptoms of asthma & chronic obstructive pulmonary disease(COPD), focusing on the difference in its usage for both the diseases and the modes of action. After the initiation of inhaled corticosteroids(ICS), long...

  • Long-term, once-daily COPD treatment.  // Clinical Advisor;Nov2013, Vol. 16 Issue 11, p40 

    The article offers information on the Breo Ellipta corticosteroid + long-acting B2-agonist drug for chronic obstructive pulmonary desease (COPD) treatment from GlaxoSmithKline.

  • COPD combination therapy questioned.  // Independent Nurse;11/2/2009, p15 

    The article discusses a Dutch study concerning the addition of long-acting beta-agonists (LABAs) to corticosteroid therapy for chronic obstructive pulmonary disease (COPD). The findings of the study negate an analysis of the Toxoplasmosis, Rubella, Cytomegalovirus and Herpes Simplex (TORCH)...

  • Bevantolol vs Propranolol: A Double-Blind Controlled Trial in Essential Hypertension. Maclean, Derek // Angiology;Jun1988, Vol. 39 Issue 6, p487 

    Bevantolol is a novel β1-selective beta-adrenoceptor antagonist. The Study Group evaluated its therapeutic utility (100–300 mg bid) compared with propranolol (80–240 mg bid) in 266 patients with mild to moderate essential hypertension (WHO Grades I and II, sitting diastolic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics